Last --
Change Today 0.00 / 0.00%
Volume 0.0
4162 On Other Exchanges
4162 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

pharmaengine inc (4162) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMAENGINE INC (4162)

Related News

No related news articles were found.

pharmaengine inc (4162) Related Businessweek News

No Related Businessweek News Found

pharmaengine inc (4162) Details

PharmaEngine, Inc., a biopharmaceutical company, is engaged in the development of drugs for the treatment of cancer and Asian prevalent diseases in Taiwan. The company develops, manufactures, and commercializes PEP02, a novel and stable nanoliposomal formulation of irinotecan, which has completed four Phase I studies and two Phase II studies for gastric and pancreatic cancers in Asia and Europe. It also develops PEP503, a crystalline hafnium oxide, which is in Phase I trial in France. PharmaEngine, Inc. has collaborations with Merrimack Pharmaceuticals, Inc.; Nanobiotix S.A.; and Guangzhou BeBetter Medicine Technology Co., Ltd. The company was founded in 2003 and is based in Taipei, Taiwan.

Founded in 2003

pharmaengine inc (4162) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmaengine inc (4162) Key Developments

PharmaEngine Inc. and Nanobiotix SA Strengthen Collaboration for a Global Pivotal Trial of NBTXR3 in Soft Tissue Sarcoma

PharmaEngine Inc. and Nanobiotix SA announced that the companies had strengthened their collaboration by jointly conducting a global pivotal trial of NBTXR3 in soft tissue sarcoma (STS) in Europe and Asia. Nanobiotix expects recruitment of the first patient in Europe by the end of 2014. In conjunction with the accelerated clinical development, PharmaEngine will make a milestone payment of $1 million to Nanobiotix. In August 2012, PharmaEngine licensed the development and commercialization rights of NBTXR3 (designated as PEP503 by PharmaEngine) in Asia-Pacific region from Nanobiotix. Nanobiotix reported results of a pilot study of STS in mid-2014. Twenty patients were enrolled and received a single intratumoral injection of NBTXR3 (PEP503), at escalating volumes, followed by five weekly sessions of standard radiotherapy (50 Gy), after which the patients underwent surgical resection. The treatment regimen was well tolerated and showed promising signs of anti-tumor activity. The positive results of the study were presented by Nanobiotix at the American Society of Clinical Oncology Annual Meeting in June 2014.

PharmaEngine Amends Cancer Drug Deal with Merrimack Pharmaceuticals

PharmaEngine announced that it amended its license agreement with Merrimack Pharmaceuticals (MACK) regarding the pancreatic cancer drug MM-398. Earlier this week MACK announced an exclusive license to Baxter International (BAX) to develop and sell MM-398 outside of the United States and Taiwan. Under the amendment, PharmaEngine receives now $7 million and another $5 million upon the approval of MM-398 by the U.S. FDA, or no later than April 30, 2015. PharmaEngine reported that it can receive up $251.5 million in the future, in addition to the license fees of $15 million already received under the deal with MACK. PharmaEngine licensed the rights of MM-398 (aka nanoliposomal irinotecan injection, nal-IRI) in Asia and Europe to MACK for $220 million plus royalties and sublicense revenue in May 2011.

PharmaEngine Inc., Annual General Meeting, Jun 11, 2014

PharmaEngine Inc., Annual General Meeting, Jun 11, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4162:TT 281.00 TWD +3.50

4162 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4162.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4162 Industry Range
Price/Earnings 100.0x
Price/Sales 113.4x
Price/Book 9.1x
Price/Cash Flow 196.3x
TEV/Sales 102.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAENGINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at